Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myelomonocytic, Acute 5Leukemia, Myeloid, Acute 5Leukemia, Monocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Leukemia 4Breast Neoplasms 4Congenital Abnormalities 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Kidney Neoplasms 2Sarcoma, Kaposi 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Carcinoma, Renal Cell 1Anemia, Refractory, with Excess of Blasts 1AIDS-related Kaposi sarcoma 1

Interventions

Cyclophosphamide 216Methotrexate 140Cytarabine 131Vincristine 110fludarabine phosphate 103Peripheral Blood Stem Cell Transplantation 98Filgrastim 92Etoposide 92Dexamethasone 89Mycophenolic Acid 71Doxorubicin 70Whole-Body Irradiation 67Mercaptopurine 66Busulfan 65Tacrolimus 64Radiotherapy 63Cyclosporine 62Prednisone 55Daunorubicin 53pegaspargase 51Asparaginase 51Rituximab 48fludarabine 47Granulocyte Colony-Stimulating Factor 46Melphalan 45Antilymphocyte Serum 43Clofarabine 42Calcium Dobesilate 38Methylprednisolone 36Leucovorin 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor Cell Lymphoblastic Leukemia-Lymphoma × valspodar × Clear all
NCT00002912 2013-02-01

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡